ICD-10-PCS Table - Anatomical Regions, Introduction (XW0)

`XW0----` ← Click code for details.
0 - Skin	`X` - External	`2` - Anacaulase-bcdb	`7` - New Technology Group 7
1 - Subcutaneous Tissue	`3` - Percutaneous	`1` - Daratumumab and Hyaluronidase-fihj	`8` - New Technology Group 8
1 - Subcutaneous Tissue	`3` - Percutaneous	`2` - Talquetamab Antineoplastic	`9` - New Technology Group 9
1 - Subcutaneous Tissue	`3` - Percutaneous	`4` - Teclistamab Antineoplastic	`8` - New Technology Group 8
1 - Subcutaneous Tissue	`3` - Percutaneous	`6` - Dasiglucagon	`A` - New Technology Group 10
1 - Subcutaneous Tissue	`3` - Percutaneous	`9` - Satralizumab-mwge	`7` - New Technology Group 7
1 - Subcutaneous Tissue	`3` - Percutaneous	`F` - Other New Technology Therapeutic Substance	`5` - New Technology Group 5
1 - Subcutaneous Tissue	`3` - Percutaneous	`G` - REGN-COV2 Monoclonal Antibody `H` - Other New Technology Monoclonal Antibody `K` - Leronlimab Monoclonal Antibody	`6` - New Technology Group 6
1 - Subcutaneous Tissue	`3` - Percutaneous	`L` - Elranatamab Antineoplastic	`9` - New Technology Group 9
1 - Subcutaneous Tissue	`3` - Percutaneous	`S` - COVID-19 Vaccine Dose 1	`6` - New Technology Group 6
1 - Subcutaneous Tissue	`3` - Percutaneous	`S` - Epcoritamab Monoclonal Antibody	`9` - New Technology Group 9
1 - Subcutaneous Tissue	`3` - Percutaneous	`T` - COVID-19 Vaccine Dose 2 `U` - COVID-19 Vaccine	`6` - New Technology Group 6
1 - Subcutaneous Tissue	`3` - Percutaneous	`V` - COVID-19 Vaccine Dose 3	`7` - New Technology Group 7
1 - Subcutaneous Tissue	`3` - Percutaneous	`W` - Caplacizumab	`5` - New Technology Group 5
1 - Subcutaneous Tissue	`3` - Percutaneous	`W` - COVID-19 Vaccine Booster	`7` - New Technology Group 7
1 - Subcutaneous Tissue	`X` - External	`2` - Anacaulase-bcdb	`7` - New Technology Group 7
2 - Muscle	`0` - Open	`D` - Engineered Allogeneic Thymus Tissue	`8` - New Technology Group 8
2 - Muscle	`3` - Percutaneous	`S` - COVID-19 Vaccine Dose 1 `T` - COVID-19 Vaccine Dose 2 `U` - COVID-19 Vaccine	`6` - New Technology Group 6
2 - Muscle	`3` - Percutaneous	`V` - COVID-19 Vaccine Dose 3 `W` - COVID-19 Vaccine Booster `X` - Tixagevimab and Cilgavimab Monoclonal Antibody `Y` - Other New Technology Monoclonal Antibody	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`0` - Brexanolone	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`0` - Spesolimab Monoclonal Antibody	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`2` - Nerinitide `3` - Durvalumab Antineoplastic	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`3` - Bentracimab, Ticagrelor Reversal Agent `4` - Cefepime-taniborbactam Anti-infective	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`5` - Narsoplimab Monoclonal Antibody	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`5` - Mosunetuzumab Antineoplastic	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`5` - Ceftobiprole Medocaril Anti-infective	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`6` - Lefamulin Anti-infective	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`6` - Terlipressin	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`6` - Afamitresgene Autoleucel Immunotherapy	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`7` - Coagulation Factor Xa, Inactivated	`2` - New Technology Group 2
3 - Peripheral Vein	`3` - Percutaneous	`7` - Trilaciclib	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`7` - Tabelecleucel Immunotherapy	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`8` - Lurbinectedin	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`8` - Treosulfan	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`8` - Obecabtagene Autoleucel	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`9` - Ceftolozane/Tazobactam Anti-infective	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`9` - Inebilizumab-cdon	`8` - New Technology Group 8
3 - Peripheral Vein	`3` - Percutaneous	`9` - Odronextamab Antineoplastic	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`A` - Cefiderocol Anti-infective	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`A` - Ciltacabtagene Autoleucel	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`B` - Cytarabine and Daunorubicin Liposome Antineoplastic	`3` - New Technology Group 3
3 - Peripheral Vein	`3` - Percutaneous	`B` - Omadacycline Anti-infective	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`B` - Amivantamab Monoclonal Antibody	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`B` - Orca-T Allogeneic T-cell Immunotherapy	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`C` - Eculizumab	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`C` - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`C` - Zanidatamab Antineoplastic	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`D` - Atezolizumab Antineoplastic	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`D` - Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`E` - Remdesivir Anti-infective	`5` - New Technology Group 5
3 - Peripheral Vein	`3` - Percutaneous	`E` - Etesevimab Monoclonal Antibody	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`F` - Other New Technology Therapeutic Substance	`3` - New Technology Group 3
3 - Peripheral Vein	`3` - Percutaneous	`F` - Other New Technology Therapeutic Substance	`5` - New Technology Group 5
3 - Peripheral Vein	`3` - Percutaneous	`F` - Bamlanivimab Monoclonal Antibody	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`F` - Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	`A` - New Technology Group 10
3 - Peripheral Vein	`3` - Percutaneous	`G` - Sarilumab	`5` - New Technology Group 5
3 - Peripheral Vein	`3` - Percutaneous	`G` - REGN-COV2 Monoclonal Antibody	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`G` - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`H` - Tocilizumab	`5` - New Technology Group 5
3 - Peripheral Vein	`3` - Percutaneous	`H` - Other New Technology Monoclonal Antibody	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`H` - Axicabtagene Ciloleucel Immunotherapy `J` - Tisagenlecleucel Immunotherapy `K` - Idecabtagene Vicleucel Immunotherapy	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`K` - Sulbactam-Durlobactam	`9` - New Technology Group 9
3 - Peripheral Vein	`3` - Percutaneous	`L` - CD24Fc Immunomodulator	`6` - New Technology Group 6
3 - Peripheral Vein	`3` - Percutaneous	`L` - Lifileucel Immunotherapy `M` - Brexucabtagene Autoleucel Immunotherapy `N` - Lisocabtagene Maraleucel Immunotherapy	`7` - New Technology Group 7
3 - Peripheral Vein	`3` - Percutaneous	`P` - Glofitamab Antineoplastic	`9` - New Technology Group 9
3 - Peripheral Vein	`3` - Percutaneous	`Q` - Tagraxofusp-erzs Antineoplastic	`5` - New Technology Group 5
3 - Peripheral Vein	`3` - Percutaneous	`Q` - Posoleucel `R` - Rezafungin	`9` - New Technology Group 9
3 - Peripheral Vein	`3` - Percutaneous	`S` - Iobenguane I-131 Antineoplastic `W` - Caplacizumab	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`0` - Brexanolone	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`0` - Spesolimab Monoclonal Antibody	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`2` - Nerinitide `3` - Durvalumab Antineoplastic	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`3` - Bentracimab, Ticagrelor Reversal Agent `4` - Cefepime-taniborbactam Anti-infective	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`5` - Narsoplimab Monoclonal Antibody	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`5` - Mosunetuzumab Antineoplastic	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`5` - Ceftobiprole Medocaril Anti-infective	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`6` - Lefamulin Anti-infective	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`6` - Terlipressin	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`6` - Afamitresgene Autoleucel Immunotherapy	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`7` - Coagulation Factor Xa, Inactivated	`2` - New Technology Group 2
4 - Central Vein	`3` - Percutaneous	`7` - Trilaciclib	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`7` - Tabelecleucel Immunotherapy	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`8` - Lurbinectedin	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`8` - Treosulfan	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`8` - Obecabtagene Autoleucel	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`9` - Ceftolozane/Tazobactam Anti-infective	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`9` - Inebilizumab-cdon	`8` - New Technology Group 8
4 - Central Vein	`3` - Percutaneous	`9` - Odronextamab Antineoplastic	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`A` - Cefiderocol Anti-infective	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`A` - Ciltacabtagene Autoleucel	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`B` - Cytarabine and Daunorubicin Liposome Antineoplastic	`3` - New Technology Group 3
4 - Central Vein	`3` - Percutaneous	`B` - Omadacycline Anti-infective	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`B` - Amivantamab Monoclonal Antibody	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`B` - Orca-T Allogeneic T-cell Immunotherapy	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`C` - Eculizumab	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`C` - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`C` - Zanidatamab Antineoplastic	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`D` - Atezolizumab Antineoplastic	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`E` - Remdesivir Anti-infective	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`E` - Etesevimab Monoclonal Antibody	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`F` - Other New Technology Therapeutic Substance	`3` - New Technology Group 3
4 - Central Vein	`3` - Percutaneous	`F` - Other New Technology Therapeutic Substance	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`F` - Bamlanivimab Monoclonal Antibody	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`F` - Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	`A` - New Technology Group 10
4 - Central Vein	`3` - Percutaneous	`G` - Sarilumab	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`G` - REGN-COV2 Monoclonal Antibody	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`G` - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`H` - Tocilizumab	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`H` - Other New Technology Monoclonal Antibody	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`H` - Axicabtagene Ciloleucel Immunotherapy `J` - Tisagenlecleucel Immunotherapy `K` - Idecabtagene Vicleucel Immunotherapy	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`K` - Sulbactam-Durlobactam	`9` - New Technology Group 9
4 - Central Vein	`3` - Percutaneous	`L` - CD24Fc Immunomodulator	`6` - New Technology Group 6
4 - Central Vein	`3` - Percutaneous	`L` - Lifileucel Immunotherapy `M` - Brexucabtagene Autoleucel Immunotherapy `N` - Lisocabtagene Maraleucel Immunotherapy	`7` - New Technology Group 7
4 - Central Vein	`3` - Percutaneous	`P` - Glofitamab Antineoplastic	`9` - New Technology Group 9
4 - Central Vein	`3` - Percutaneous	`Q` - Tagraxofusp-erzs Antineoplastic	`5` - New Technology Group 5
4 - Central Vein	`3` - Percutaneous	`Q` - Posoleucel `R` - Rezafungin	`9` - New Technology Group 9
4 - Central Vein	`3` - Percutaneous	`S` - Iobenguane I-131 Antineoplastic `W` - Caplacizumab	`5` - New Technology Group 5
5 - Peripheral Artery	`3` - Percutaneous	`T` - Melphalan Hydrochloride Antineoplastic	`9` - New Technology Group 9
D - Mouth and Pharynx	`X` - External	`3` - Maribavir Anti-infective	`8` - New Technology Group 8
D - Mouth and Pharynx	`X` - External	`6` - Lefamulin Anti-infective	`6` - New Technology Group 6
D - Mouth and Pharynx	`X` - External	`8` - Uridine Triacetate	`2` - New Technology Group 2
D - Mouth and Pharynx	`X` - External	`F` - Other New Technology Therapeutic Substance	`5` - New Technology Group 5
D - Mouth and Pharynx	`X` - External	`J` - Quizartinib Antineoplastic	`9` - New Technology Group 9
D - Mouth and Pharynx	`X` - External	`K` - Sabizabulin	`8` - New Technology Group 8
D - Mouth and Pharynx	`X` - External	`M` - Baricitinib	`6` - New Technology Group 6
D - Mouth and Pharynx	`X` - External	`N` - SER-109	`9` - New Technology Group 9
D - Mouth and Pharynx	`X` - External	`R` - Fostamatinib	`7` - New Technology Group 7
G - Upper GI	`7` - Via Natural or Artificial Opening	`3` - Maribavir Anti-infective `K` - Sabizabulin	`8` - New Technology Group 8
G - Upper GI	`7` - Via Natural or Artificial Opening	`M` - Baricitinib	`6` - New Technology Group 6
G - Upper GI	`7` - Via Natural or Artificial Opening	`R` - Fostamatinib	`7` - New Technology Group 7
G - Upper GI	`8` - Via Natural or Artificial Opening Endoscopic	`8` - Mineral-based Topical Hemostatic Agent	`6` - New Technology Group 6
H - Lower GI	`7` - Via Natural or Artificial Opening	`3` - Maribavir Anti-infective `K` - Sabizabulin	`8` - New Technology Group 8
H - Lower GI	`7` - Via Natural or Artificial Opening	`M` - Baricitinib	`6` - New Technology Group 6
H - Lower GI	`7` - Via Natural or Artificial Opening	`R` - Fostamatinib	`7` - New Technology Group 7
H - Lower GI	`7` - Via Natural or Artificial Opening	`X` - Broad Consortium Microbiota-based Live Biotherapeutic Suspension	`8` - New Technology Group 8
H - Lower GI	`8` - Via Natural or Artificial Opening Endoscopic	`8` - Mineral-based Topical Hemostatic Agent	`6` - New Technology Group 6
J - Coronary Artery, One Artery K - Coronary Artery, Two Arteries L - Coronary Artery, Three Arteries M - Coronary Artery, Four or More Arteries	`3` - Percutaneous	`H` - Paclitaxel-Coated Balloon Technology, One Balloon `J` - Paclitaxel-Coated Balloon Technology, Two Balloons `K` - Paclitaxel-Coated Balloon Technology, Three Balloons `L` - Paclitaxel-Coated Balloon Technology, Four or More Balloons	`A` - New Technology Group 10
Q - Cranial Cavity and Brain	`3` - Percutaneous	`1` - Eladocagene exuparvovec	`6` - New Technology Group 6
U - Joints	`0` - Open	`G` - Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System	`A` - New Technology Group 10
V - Bones	`0` - Open	`P` - Antibiotic-eluting Bone Void Filler	`7` - New Technology Group 7
V - Bones	`3` - Percutaneous	`W` - AGN1 Bone Void Filler	`A` - New Technology Group 10

0 - Skin

X - External

2 - Anacaulase-bcdb

7 - New Technology Group 7

1 - Subcutaneous Tissue

3 - Percutaneous

1 - Daratumumab and Hyaluronidase-fihj

8 - New Technology Group 8

1 - Subcutaneous Tissue

3 - Percutaneous

2 - Talquetamab Antineoplastic

9 - New Technology Group 9

1 - Subcutaneous Tissue

3 - Percutaneous

4 - Teclistamab Antineoplastic

8 - New Technology Group 8

1 - Subcutaneous Tissue

3 - Percutaneous

6 - Dasiglucagon

A - New Technology Group 10

1 - Subcutaneous Tissue

3 - Percutaneous

9 - Satralizumab-mwge

7 - New Technology Group 7

1 - Subcutaneous Tissue

3 - Percutaneous

F - Other New Technology Therapeutic Substance

5 - New Technology Group 5

1 - Subcutaneous Tissue

3 - Percutaneous

G - REGN-COV2 Monoclonal Antibody
H - Other New Technology Monoclonal Antibody
K - Leronlimab Monoclonal Antibody

6 - New Technology Group 6

1 - Subcutaneous Tissue

3 - Percutaneous

L - Elranatamab Antineoplastic

9 - New Technology Group 9

1 - Subcutaneous Tissue

3 - Percutaneous

S - COVID-19 Vaccine Dose 1

6 - New Technology Group 6

1 - Subcutaneous Tissue

3 - Percutaneous

S - Epcoritamab Monoclonal Antibody

9 - New Technology Group 9

1 - Subcutaneous Tissue

3 - Percutaneous

T - COVID-19 Vaccine Dose 2
U - COVID-19 Vaccine

6 - New Technology Group 6

1 - Subcutaneous Tissue

3 - Percutaneous

V - COVID-19 Vaccine Dose 3

7 - New Technology Group 7

1 - Subcutaneous Tissue

3 - Percutaneous

W - Caplacizumab

5 - New Technology Group 5

1 - Subcutaneous Tissue

3 - Percutaneous

W - COVID-19 Vaccine Booster

7 - New Technology Group 7

1 - Subcutaneous Tissue

X - External

2 - Anacaulase-bcdb

7 - New Technology Group 7

2 - Muscle

0 - Open

D - Engineered Allogeneic Thymus Tissue

8 - New Technology Group 8

2 - Muscle

3 - Percutaneous

S - COVID-19 Vaccine Dose 1
T - COVID-19 Vaccine Dose 2
U - COVID-19 Vaccine

6 - New Technology Group 6

2 - Muscle

3 - Percutaneous

V - COVID-19 Vaccine Dose 3
W - COVID-19 Vaccine Booster
X - Tixagevimab and Cilgavimab Monoclonal Antibody
Y - Other New Technology Monoclonal Antibody

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

0 - Brexanolone

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

0 - Spesolimab Monoclonal Antibody

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

2 - Nerinitide
3 - Durvalumab Antineoplastic

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

3 - Bentracimab, Ticagrelor Reversal Agent
4 - Cefepime-taniborbactam Anti-infective

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

5 - Narsoplimab Monoclonal Antibody

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

5 - Mosunetuzumab Antineoplastic

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

5 - Ceftobiprole Medocaril Anti-infective

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

6 - Lefamulin Anti-infective

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

6 - Terlipressin

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

6 - Afamitresgene Autoleucel Immunotherapy

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

7 - Coagulation Factor Xa, Inactivated

2 - New Technology Group 2

3 - Peripheral Vein

3 - Percutaneous

7 - Trilaciclib

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

7 - Tabelecleucel Immunotherapy

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

8 - Lurbinectedin

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

8 - Treosulfan

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

8 - Obecabtagene Autoleucel

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

9 - Ceftolozane/Tazobactam Anti-infective

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

9 - Inebilizumab-cdon

8 - New Technology Group 8

3 - Peripheral Vein

3 - Percutaneous

9 - Odronextamab Antineoplastic

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

A - Cefiderocol Anti-infective

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

A - Ciltacabtagene Autoleucel

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

B - Cytarabine and Daunorubicin Liposome Antineoplastic

3 - New Technology Group 3

3 - Peripheral Vein

3 - Percutaneous

B - Omadacycline Anti-infective

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

B - Amivantamab Monoclonal Antibody

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

B - Orca-T Allogeneic T-cell Immunotherapy

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

C - Eculizumab

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

C - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

C - Zanidatamab Antineoplastic

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

D - Atezolizumab Antineoplastic

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

D - Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

E - Remdesivir Anti-infective

5 - New Technology Group 5

3 - Peripheral Vein

3 - Percutaneous

E - Etesevimab Monoclonal Antibody

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

F - Other New Technology Therapeutic Substance

3 - New Technology Group 3

3 - Peripheral Vein

3 - Percutaneous

F - Other New Technology Therapeutic Substance

5 - New Technology Group 5

3 - Peripheral Vein

3 - Percutaneous

F - Bamlanivimab Monoclonal Antibody

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

F - Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy

A - New Technology Group 10

3 - Peripheral Vein

3 - Percutaneous

G - Sarilumab

5 - New Technology Group 5

3 - Peripheral Vein

3 - Percutaneous

G - REGN-COV2 Monoclonal Antibody

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

G - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

H - Tocilizumab

5 - New Technology Group 5

3 - Peripheral Vein

3 - Percutaneous

H - Other New Technology Monoclonal Antibody

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

H - Axicabtagene Ciloleucel Immunotherapy
J - Tisagenlecleucel Immunotherapy
K - Idecabtagene Vicleucel Immunotherapy

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

K - Sulbactam-Durlobactam

9 - New Technology Group 9

3 - Peripheral Vein

3 - Percutaneous

L - CD24Fc Immunomodulator

6 - New Technology Group 6

3 - Peripheral Vein

3 - Percutaneous

L - Lifileucel Immunotherapy
M - Brexucabtagene Autoleucel Immunotherapy
N - Lisocabtagene Maraleucel Immunotherapy

7 - New Technology Group 7

3 - Peripheral Vein

3 - Percutaneous

P - Glofitamab Antineoplastic

9 - New Technology Group 9

3 - Peripheral Vein

3 - Percutaneous

Q - Tagraxofusp-erzs Antineoplastic

5 - New Technology Group 5

3 - Peripheral Vein

3 - Percutaneous

Q - Posoleucel
R - Rezafungin

9 - New Technology Group 9

3 - Peripheral Vein

3 - Percutaneous

S - Iobenguane I-131 Antineoplastic
W - Caplacizumab

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

0 - Brexanolone

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

0 - Spesolimab Monoclonal Antibody

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

2 - Nerinitide
3 - Durvalumab Antineoplastic

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

3 - Bentracimab, Ticagrelor Reversal Agent
4 - Cefepime-taniborbactam Anti-infective

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

5 - Narsoplimab Monoclonal Antibody

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

5 - Mosunetuzumab Antineoplastic

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

5 - Ceftobiprole Medocaril Anti-infective

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

6 - Lefamulin Anti-infective

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

6 - Terlipressin

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

6 - Afamitresgene Autoleucel Immunotherapy

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

7 - Coagulation Factor Xa, Inactivated

2 - New Technology Group 2

4 - Central Vein

3 - Percutaneous

7 - Trilaciclib

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

7 - Tabelecleucel Immunotherapy

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

8 - Lurbinectedin

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

8 - Treosulfan

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

8 - Obecabtagene Autoleucel

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

9 - Ceftolozane/Tazobactam Anti-infective

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

9 - Inebilizumab-cdon

8 - New Technology Group 8

4 - Central Vein

3 - Percutaneous

9 - Odronextamab Antineoplastic

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

A - Cefiderocol Anti-infective

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

A - Ciltacabtagene Autoleucel

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

B - Cytarabine and Daunorubicin Liposome Antineoplastic

3 - New Technology Group 3

4 - Central Vein

3 - Percutaneous

B - Omadacycline Anti-infective

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

B - Amivantamab Monoclonal Antibody

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

B - Orca-T Allogeneic T-cell Immunotherapy

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

C - Eculizumab

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

C - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

C - Zanidatamab Antineoplastic

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

D - Atezolizumab Antineoplastic

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

E - Remdesivir Anti-infective

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

E - Etesevimab Monoclonal Antibody

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

F - Other New Technology Therapeutic Substance

3 - New Technology Group 3

4 - Central Vein

3 - Percutaneous

F - Other New Technology Therapeutic Substance

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

F - Bamlanivimab Monoclonal Antibody

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

F - Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy

A - New Technology Group 10

4 - Central Vein

3 - Percutaneous

G - Sarilumab

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

G - REGN-COV2 Monoclonal Antibody

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

G - Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

H - Tocilizumab

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

H - Other New Technology Monoclonal Antibody

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

H - Axicabtagene Ciloleucel Immunotherapy
J - Tisagenlecleucel Immunotherapy
K - Idecabtagene Vicleucel Immunotherapy

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

K - Sulbactam-Durlobactam

9 - New Technology Group 9

4 - Central Vein

3 - Percutaneous

L - CD24Fc Immunomodulator

6 - New Technology Group 6

4 - Central Vein

3 - Percutaneous

L - Lifileucel Immunotherapy
M - Brexucabtagene Autoleucel Immunotherapy
N - Lisocabtagene Maraleucel Immunotherapy

7 - New Technology Group 7

4 - Central Vein

3 - Percutaneous

P - Glofitamab Antineoplastic

9 - New Technology Group 9

4 - Central Vein

3 - Percutaneous

Q - Tagraxofusp-erzs Antineoplastic

5 - New Technology Group 5

4 - Central Vein

3 - Percutaneous

Q - Posoleucel
R - Rezafungin

9 - New Technology Group 9

4 - Central Vein

3 - Percutaneous

S - Iobenguane I-131 Antineoplastic
W - Caplacizumab

5 - New Technology Group 5

5 - Peripheral Artery

3 - Percutaneous

T - Melphalan Hydrochloride Antineoplastic

9 - New Technology Group 9

D - Mouth and Pharynx

X - External

3 - Maribavir Anti-infective

8 - New Technology Group 8

D - Mouth and Pharynx

X - External

6 - Lefamulin Anti-infective

6 - New Technology Group 6

D - Mouth and Pharynx

X - External

8 - Uridine Triacetate

2 - New Technology Group 2

D - Mouth and Pharynx

X - External

F - Other New Technology Therapeutic Substance

5 - New Technology Group 5

D - Mouth and Pharynx

X - External

J - Quizartinib Antineoplastic

9 - New Technology Group 9

D - Mouth and Pharynx

X - External

K - Sabizabulin

8 - New Technology Group 8

D - Mouth and Pharynx

X - External

M - Baricitinib

6 - New Technology Group 6

D - Mouth and Pharynx

X - External

N - SER-109

9 - New Technology Group 9

D - Mouth and Pharynx

X - External

R - Fostamatinib

7 - New Technology Group 7

G - Upper GI

7 - Via Natural or Artificial Opening

3 - Maribavir Anti-infective
K - Sabizabulin

8 - New Technology Group 8

G - Upper GI

7 - Via Natural or Artificial Opening

M - Baricitinib

6 - New Technology Group 6

G - Upper GI

7 - Via Natural or Artificial Opening

R - Fostamatinib

7 - New Technology Group 7

G - Upper GI

8 - Via Natural or Artificial Opening Endoscopic

8 - Mineral-based Topical Hemostatic Agent

6 - New Technology Group 6

H - Lower GI

7 - Via Natural or Artificial Opening

3 - Maribavir Anti-infective
K - Sabizabulin

8 - New Technology Group 8

H - Lower GI

7 - Via Natural or Artificial Opening

M - Baricitinib

6 - New Technology Group 6

H - Lower GI

7 - Via Natural or Artificial Opening

R - Fostamatinib

7 - New Technology Group 7

H - Lower GI

7 - Via Natural or Artificial Opening

X - Broad Consortium Microbiota-based Live Biotherapeutic Suspension

8 - New Technology Group 8

H - Lower GI

8 - Via Natural or Artificial Opening Endoscopic

8 - Mineral-based Topical Hemostatic Agent

6 - New Technology Group 6

J - Coronary Artery, One Artery
K - Coronary Artery, Two Arteries
L - Coronary Artery, Three Arteries
M - Coronary Artery, Four or More Arteries

3 - Percutaneous

H - Paclitaxel-Coated Balloon Technology, One Balloon
J - Paclitaxel-Coated Balloon Technology, Two Balloons
K - Paclitaxel-Coated Balloon Technology, Three Balloons
L - Paclitaxel-Coated Balloon Technology, Four or More Balloons

A - New Technology Group 10

Q - Cranial Cavity and Brain

3 - Percutaneous

1 - Eladocagene exuparvovec

6 - New Technology Group 6

U - Joints

0 - Open

G - Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System

A - New Technology Group 10

V - Bones

0 - Open

P - Antibiotic-eluting Bone Void Filler

7 - New Technology Group 7

V - Bones

3 - Percutaneous

W - AGN1 Bone Void Filler

A - New Technology Group 10

ICD-10-PCS Table XW0 for Anatomical Regions, Introduction

ICD-10-PCS Table `XW0`
for Anatomical Regions, Introduction